Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.55 |
| ▸ | CDK2 | P24941 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6607604 | 0.82 | CDK5 (0.64) | KMT2ARAB9AMEN1CDK5MAPK1 | |
| SCHEMBL6611369 | 0.80 | CDK5 (0.72) | KMT2ARAB9AMEN1CDK5MAPK1 | |
| SCHEMBL6617607 | 0.72 | CDK5 (0.62) | KMT2ARAB9AMEN1CDK5MAPK1 | |
| SCHEMBL7753417 | 0.69 | CCNA2 (0.68) | KMT2ARAB9AMEN1CDK5MAPK1 | |
| SCHEMBL7756151 | 0.68 | KMT2A (0.71) | KMT2ARAB9AMEN1CDK5MAPK1 | |
| SCHEMBL6193441 | 0.68 | CCNT1 (0.55) | KMT2ACDK5CCNA2CDK2CLK2 | |
| SCHEMBL15757257 | 0.67 | CYP2C19 (0.49) | KMT2ARAB9AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL5803203 | 0.67 | GSK3B (0.49) | KMT2ARAB9AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL7485927 | 0.65 | KMT2A (0.48) | KMT2ARAB9AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL3989809 | 0.65 | MALT1 (0.54) | KMT2ARAB9AMEN1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040210063-A1 | Novel 2,4-diaminothiazole derivatives | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | US | disclosed |
| EP-1417188-A1 | NOVEL 2,4-DIAMINOTHIAZOLE DERIVATIVES | Novo Nordisk A/S (DK) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003011843-A1 | NOVEL 2,4-DIAMINOTHIAZOLE DERIVATIVES | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210063-A1 | Novel 2,4-diaminothiazole derivatives | GSK3B, GSK3A, GYS2 | KMT2A 2788/4885RAB9A 4390/4885MEN1 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.